+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of post-remission therapy mainly with compound huangdai tablet on long-term survival of patients with acute promyelocytic leukemia



Effect of post-remission therapy mainly with compound huangdai tablet on long-term survival of patients with acute promyelocytic leukemia



Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi 30(12): 1253-1256



To investigate the effect of post-remission therapy mainly with Compound Huangdai Tablet (CHDT) on long-term survival of patients with acute promyelocytic leukemia (APL). One hundred and twelve APL patients were treated after remission mainly with CHDT administered alternately with chemotherapeutic projects such as HACP, HAOP, HAEP and HAMP. The relapse rate and relapse-free survival (RFS) rate in them were estimated by bone marrow examination. The total relapse rate was 14.29% (16/112), and the median time of relapse was 12.5 (4-67) months. Patients were followed up for 1-72 months, the median follow-up time being 59 months. The actual RFS rate of 1-, 2-, 3-, 4-, 5- and 6-year was 92.86%, 89.29%, 88.39%, 87.50%, 86.61% and 85.71%, respectively, while the estimated RFS rate (%) of corresponding year was 92.45 +/- 2.57, 88.25 +/- 3.20, 87.09 +/- 3.36, 85.89 +/- 3.52, 84.44 +/- 3.75 and 82.78 +/- 4.03 respectively; the relapse rate in patients who received treatment after complete response for <10 courses group was 34.29%, while in those treated for > or = 10 courses was 5.19%; and the RFS rate in them was 65.71% and 94.81% respectively, the difference between groups was statistically significant (P<0.01). The post-remission therapy mainly with CHDT is an effective and feasible program for the treatment of APL.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 052823161

Download citation: RISBibTeXText

PMID: 21302484


Related references

Effects of all-trans retinoic acid and compound huangdai tablet sequential maintenance treatment on the long-term efficacy of acute promyelocytic leukemia patients. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi 32(11): 1473-1476, 2014

Compound huangdai tablet as induction therapy for 193 patients with acute promyelocytic leukemia. Zhonghua Xue Ye Xue Za Zhi 30(7): 440-442, 2011

The effects of different post-remission treatment on long-term survival of acute promyelocytic leukemia. Zhonghua Nei Ke Za Zhi 45(9): 741-743, 2006

Pulsed ATRA as single therapy restores long-term remission in PML-RARalpha-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study. Leukemia 15(11): 1696-1700, 2001

Pilot study of all-trans retinoic acid as post-remission therapy in patients with acute promyelocytic leukemia. Leukemia 9(1): 15-18, 1995

Study on remission induction and post-remission therapy with all-trans retinoic acid in acute promyelocytic leukemia. Leukemia (Basingstoke) 8(6): 1088, 1994

Absence of detectable PML-RAR-alpha fusion transcripts in long-term remission patients after BMT for acute promyelocytic leukemia. Bone Marrow Transplantation 19(7): 679-683, 1997

Analysis of long-term outcome of patients with acute promyelocytic leukemia treated with different regimens after complete remission. Tumor: 2, 150-152, 2008

Subclinical anthracycline cardiotoxicity in patients with acute promyelocytic leukemia in long-term remission after the AIDA protocol. Congestive Heart Failure 18(4): 217-221, 2012

Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia. Thrombosis & Haemostasis 77(4): 641-645, 1997

Induction therapy of acute promyelocytic leukemia with all-trans retinoic acid: a case, followed by conventional post-remission chemotherapy in complete remission. Japanese Journal of Clinical Hematology 33(12): 1880-1883, 1992

Long-term results of bone marrow transplantation as post-remission therapy in adult acute lymphoblastic leukemia Experience of a single institution in 88 patients. British Journal of Haematology 93(SUPPL 2): 61, 1996

Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission. Blood 82(12): 3556-3559, 1993

Relapse of acute promyelocytic leukemia after 10 years long-term remission. Leukemia & Lymphoma 43(3): 679-680, 2002

Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up. Leukemia Research 39(5): 520-524, 2015